Jump to content

New Cancer Drug in Phase 3 Trials

Recommended Posts

http://www.forbes.com/feeds/afx/2007/08 ... tner=email

PARIS (Thomson Financial) - Sanofi-Aventis and Regeneron Pharmaceuticals Inc have begun two phase 3 trials of a jointly-developed drug on patients with prostate cancer and non-small cell lung cancer.

Aflibercept is an anti-angiogenic agent targeting Vascular Endothelial Growth Factor (VEGF). It is designed to be used in conjunction with chemotherapy regimens.

The two trials will be double-blind and placebo-controlled, Regeneron said.

Sanofi-Aventis will provide an update of the broad-based clinical development programme planned for the drug as well as further details on the trials at its research and development day on September 17.

Sanofi-Aventis said in June it would start seeking regulatory approval as early as next year to market the drug.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.